SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MultiCell Technologies, Inc.
MCET 0.000001000-90.0%Jun 6 1:41 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: RWS who wrote (30)1/31/2005 2:50:50 PM
From: RWS  Read Replies (1) of 237
 
From Raging Bull post. MUCL immortalized hepatocytes will be discussed in upcoming Pfizer report as suitable for inhibition tests as well as induction tests for new drug candidates.

RWS

-----------------------------------------------------

In a January 13, 2004 paper titled:
"Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line" Pfizer wrote re: Fa2N-4:

"In addition, it shows the potential of these cells [Fa2N-4] for alternative applications, such as CYP inhibition or metabolite generation."

Pfizer, [representing XenoTech] once again presents Fa2N-4 at DDI-2005, June 15-17, 2005 at the Bell Harbor Conference Center, Seattle, WA, USA

A Combined Model Approach for Studying CYP450 Enzyme Induction and Inhibition (Odette A. Fahmi, Pfizer Inc.; Groton, CT) It has been a common practice to study P450 induction using primary hepatocyte cultures, while inhibition and time-dependent inactivation studies are investigated using human liver microsomes. We investigated the use of a novel human hepatocyte clone (Fa2N-4) as an alternative reagent for identifying both P450 inducers and inhibitors. Enzyme activity and induction levels from total RNA extracts from Fa2N-4 cells treated with a panel of known inducers and known time-dependent inactivators are measured simultaneously. This presentation reviews the current status of predicting CYP450 net outcome effect.

isciencex.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News